Myocardial T2 Mapping in Patients With Hypertrophic Cardiomyopathy

Amano, Yasuo; Yanagisawa, Fumi; Tachi, Masaki; Hashimoto, Hidenobu; Imai, Shogo; Kumita, Shin‐ichiro

doi:10.1097/rct.0000000000000521

Cited by 20 publications

(22 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16). In that same study [161] the T 2 values were measured in the patient myocardium with visually high T 2 , which was present in 38% of the patients. For the patients without LGE in that study the myocardial T 2 value of 48.8 ± 2.4 ms was not significantly different from controls.…”

Section: Hypertrophic Cardiomyopathymentioning

confidence: 92%

See 1 more Smart Citation

Cardiovascular magnetic resonance native T2 and T2* quantitative values for cardiomyopathies and heart transplantations: a systematic review and meta-analysis

Snel

Boomen

Hernández

et al. 2020

Journal of Cardiovascular Magnetic Resonance

View full text Add to dashboard Cite

Background: The clinical application of cardiovascular magnetic resonance (CMR) T 2 and T 2 * mapping is currently limited as ranges for healthy and cardiac diseases are poorly defined. In this meta-analysis we aimed to determine the weighted mean of T 2 and T 2 * mapping values in patients with myocardial infarction (MI), heart transplantation, non-ischemic cardiomyopathies (NICM) and hypertension, and the standardized mean difference (SMD) of each population with healthy controls. Additionally, the variation of mapping outcomes between studies was investigated. Methods: The PRISMA guidelines were followed after literature searches on PubMed and Embase. Studies reporting CMR T 2 or T 2 * values measured in patients were included. The SMD was calculated using a random effects model and a meta-regression analysis was performed for populations with sufficient published data. Results: One hundred fifty-four studies, including 13,804 patient and 4392 control measurements, were included. T 2 values were higher in patients with MI, heart transplantation, sarcoidosis, systemic lupus erythematosus, amyloidosis, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and myocarditis (

show abstract

Section: Hypertrophic Cardiomyopathymentioning

confidence: 92%

“…5). One study reported T 2 values in controls of 48.1 ± 3.2 ms suggesting significantly higher T 2 values in HCM patients [161] (SMD = 1.95, 95% Cl [0.93, 2.97], I 2 = N/A, P < 0.01, Fig. 16).…”

Section: Hypertrophic Cardiomyopathymentioning

confidence: 99%

Cardiovascular magnetic resonance native T2 and T2* quantitative values for cardiomyopathies and heart transplantations: a systematic review and meta-analysis

Snel

Boomen

Hernández

et al. 2020

Journal of Cardiovascular Magnetic Resonance

View full text Add to dashboard Cite

show abstract

“…While Huan et al showed that T2 mapping could play a role in supporting the early diagnosis of HCM [ 46 ], Amano et al demonstrated that the presence of increased T2 values in HCM patients was associated with an increase in troponin T and brain natriuretic peptide levels (BNP), underlining the potential role of T2 information in recognizing more aggressive forms characterized by significant myocardial injury [ 50 ].…”

Section: Hypertrophic Cardiomyopathymentioning

confidence: 99%

Role of CMR Mapping Techniques in Cardiac Hypertrophic Phenotype

et al. 2020

View full text Add to dashboard Cite

Non-ischemic cardiomyopathies represent a heterogeneous group of myocardial diseases potentially leading to heart failure, life-threatening arrhythmias, and eventually death. Myocardial dysfunction is associated with different underlying pathological processes, ultimately inducing changes in morphological appearance. Thus, classification based on presenting morphological phenotypes has been proposed, i.e., dilated, hypertrophic, restrictive, and right ventricular cardiomyopathies. In light of the key diagnostic and prognostic role of morphological and functional features, cardiovascular imaging has emerged as key element in the clinical workflow of suspected cardiomyopathies, and above all, cardiovascular magnetic resonance (CMR) represents the ideal technique to be used: thanks to its physical principles, besides optimal spatial and temporal resolutions, incomparable contrast resolution allows to assess myocardial tissue abnormalities in detail. Traditionally, weighted images and late enhancement images after gadolinium-based contrast agent administration have been used to perform tissue characterization, but in the last decade quantitative assessment of pre-contrast longitudinal relaxation time (native T1), post-contrast longitudinal relaxation time (post-contrast T1) and transversal relaxation time (T2), all displayed with dedicated pixel-wise color-coded maps (mapping), has contributed to give precious knowledge insight, with positive influence of diagnostic accuracy and prognosis assessment, mostly in the setting of the hypertrophic phenotype. This review aims to describe the available evidence of the role of mapping techniques in the assessment of hypertrophic phenotype, and to suggest their integration in the routine CMR evaluation of newly diagnosed cardiomyopathies with increased wall thickness.

show abstract

“…T 2 -weighted imaging in combination with double inversion-recovery black blood preparation shows myocardial edema or inflammation associated with HCM, which may be related to chest pain, syncope, or increase in troponin T. 12 , 13 , 17 , 31 Myocardial hyperintensity on the T 2 -weighted image often locates within LGE areas ( Fig. 10 ), but can locate outside LGE.…”

Section: Introductionmentioning

confidence: 99%

“… 36 T 2 mapping is useful for confirming the presence of myocardial hyperintensity on T 2 -weighted images. 17 Nonetheless, the clinical relevance of T 1 and T 2 mapping for risk stratification of HCM has not been confirmed so far.…”

Section: Introductionmentioning

confidence: 99%

Cardiac MR Imaging of Hypertrophic Cardiomyopathy: Techniques, Findings, and Clinical Relevance

Amano

Kitamura

Takano

et al. 2018

MRMS

Self Cite

View full text Add to dashboard Cite

Hypertrophic cardiomyopathy (HCM) is a relatively common myocardial genetic disease having a wide variety of symptoms and prognoses. The most serious complications of HCM are sudden cardiac death induced by ventricular arrhythmia or inappropriate changes in blood pressure, and heart failure. Cardiac MR imaging is a valuable imaging method for detecting HCM because of its accurate measurement of wall thickness and myocardial mass without limited view and the unique ability of late gadolinium enhancement (LGE) to identify myocardial fibrosis related to the prognosis of HCM. Tagging and T1 or T2 mapping MR imaging techniques have emerged as quantitative methods for the evaluation of disease severity. In this review, we introduce the MR imaging techniques applied to HCM and demonstrate the typical phenotypes and some morphological characteristics of HCM. In addition, we discuss the clinical relevance of MR imaging for risk stratification and management of HCM.

show abstract

Myocardial T2 Mapping in Patients With Hypertrophic Cardiomyopathy

Abstract: T2 mapping identified myocardial injuries suggested by the laboratory data in HCM.

Cited by 20 publications

References 24 publications

Cardiovascular magnetic resonance native T2 and T2* quantitative values for cardiomyopathies and heart transplantations: a systematic review and meta-analysis

Cardiovascular magnetic resonance native T2 and T2* quantitative values for cardiomyopathies and heart transplantations: a systematic review and meta-analysis

Role of CMR Mapping Techniques in Cardiac Hypertrophic Phenotype

Cardiac MR Imaging of Hypertrophic Cardiomyopathy: Techniques, Findings, and Clinical Relevance

Contact Info

Product

Resources

About